HMGA2 and breast cancer: A codelivery therapy that inhibits HMGA2 by siRNA and acts on DNA by doxorubicin showed efficacy in CRC and the same dual treatment inhibits cell growth, vimentin (stemness marker), and MMP9 (invasion marker) in breast cancer cells [180, 181].